Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5‐hydroxytryptamine‐3 antiemetics: A University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program study of 360 cancer patients treated in the community - Hickok, Jane T.; Roscoe, Joseph A.; Morrow, Gary R.; King, David K.; Atkins, James N.; Fitch, Tom R. (Cancer, 2003)
Keywords: Adult; Aged; Aged, 80 and over; Antiemetics - therapeutic use; Antineoplastic Agents - adverse effects; Biological and medical sciences; Carboplatin - adverse effects; Cisplatin - adverse effects; Doxorubicin - adverse effects; Drug toxicity and drugs side effects treatment; Female; Humans; Male; Medical sciences; Middle Aged; Nausea - chemically induced; Nausea - prevention & control; Pharmacology. Drug treatments; Receptors, Serotonin - drug effects; Receptors, Serotonin, 5-HT3; Serotonin - therapeutic use; Toxicity: digestive system; Vomiting - chemically induced; Vomiting - prevention & control; Antineoplastic agent; Chemoprophylaxis; Toxicity; delayed nausea; emesis; Doxorubicin; Prevention; Isomerases; delayed emesis; Vomiting; Complication; Platinum II Complexes; Human; DNA topoisomerase (ATP-hydrolysing); Enzyme; Serotonin antagonist; Enzyme inhibitor; Nausea; Malignant tumor; Cisplatin; serotonin receptor antagonist; Alkylating agent; Antibiotic; Chemotherapy; Treatment; 5-HT3 Serotonine receptor; Carboplatin; Digestive diseases; Anthracyclins; Antiemetic; Ondansetron